Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749580 · ClinicalTrials.gov registry record · NA
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
A NA study, sponsored by University of South Florida.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00749580 is a NA study that has completed, run by University of South Florida. The registered enrollment target is 46 participants.
The verdict
NCT00749580, a NA study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
Interventions
- DRUG Switch NRTIs as a Backbone to Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749580
The ClinicalTrials.gov registry entry for NCT00749580 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Switch NRTIs as a Backbone to Raltegravir is the first listed.
NCT00749580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749580 about?
NCT00749580 is a clinical study titled "A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen". The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
What is the current status of trial NCT00749580?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2008-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00749580?
The interventions under investigation include: Switch NRTIs as a Backbone to Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00749580?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.